^
    Back
    Association details:
    Biomarker:NRAS wild-type
    Cancer:Colon Cancer
    Drug:Erbitux (cetuximab) (EGFR inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    Colon Cancer...SYSTEMIC THERAPY FOR ADVANCED OR METASTATIC DISEASE - CHEMOTHERAPY REGIMENS...FOLFIRINOX or mFOLFIRINOX + cetuximab (KRAS/NRAS/BRAF WT and left-sided tumors only)...Irinotecan + cetuximab (KRAS/NRAS/BRAF WT and left-sided tumors only)...FOLFOX + cetuximab (KRAS/NRAS/BRAF WT and left-sided tumors only)...FOLFIRI + cetuximab (KRAS/NRAS/BRAF WT and left-sided tumors only)
    Secondary therapy:
    FOLFOX; FOLFIRINOX; irinotecan; FOLFIRI
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrialsregister.eu
    Title:

    Multicenter prospective single-arm study investigating the efficacy and safety of second-line cetuximab plus chemotherapy treatment in initially RAS-mt mCRC patients who converted to RAS-wt at the time of first progression Studio di fase II a singolo braccio di terapia di II linea con cetuximab e chemioterapia in pazienti con carcinoma colorettale metastatico KRAS e NRAS mutato alla diagnosi con assenza di mutazioni di KRAS/NRAS su plasma alla progressione da prima linea

    Excerpt:
    ...- KRAS/NRAS-wt status, tested on ctDNA, at the time of progression after first line treatment- Life expectancy of at least 3 months; • Diagnosi istologica di adenocarcinoma del colon-retto• KRAS/NRAS mutato su biopsia tissutale (tumore primitivo /metastasi) al momento della diagnosi• Evidenza radiologica di progressione di malattia dopo prima linea con chemioterapia e bevacizumab• Malattia misurabile secondo criteri RECIST (RECIST criteria, vers.1.1); • Uomo o donna, età > 18 anni • ECOG Performance Status = 2; • Adeguata funzionalità ematologica, epatica e renale valutata entro 14 giorni dall’inizio del trattamento in studio Adequate bone marrow function (without hematopoietic growth factor or transfusion support within 14 days prior to study enrollment), including:a. ...
    Trial ID:
    2019-001328-36
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Metastatic Colorectal Cancer (RAS-wildtype) After Response to First-line Treatment With FOLFIR Plus Cetuximab

    Excerpt:
    ...- Proof of a RAS wild-type tumour (KRAS and NRAS exons 2-4) in a tumour biopsy (metastasis) within 4 weeks before randomisation...
    Trial ID:
    FIRE-4
    More C2 evidence
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    FOLFOXIRI With or Without Cetuximab as First-line Treatment of Patients With Non-resectable Liver - Only Metastatic Colorectal Cancer

    Excerpt:
    ...- The colorectal primary tumor or metastatic tumor must be determined to be KRAS and NRAS wild-type....
    Trial ID:
    FOCULM